Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL2429781 | 0.92 | SMN1; SMN2 (0.38) | SMN1; SMN2TP53ALDH1A1POLBGAA | |
| SCHEMBL2432116 | 0.79 | SMN1; SMN2 (0.38) | SMN1; SMN2TP53ALDH1A1POLBGAA | |
| SCHEMBL2432698 | 0.77 | SMN1; SMN2 (0.39) | SMN1; SMN2TP53ALDH1A1POLBGAA | |
| SCHEMBL2432697 | 0.77 | SMN1; SMN2 (0.39) | SMN1; SMN2TP53ALDH1A1POLBGAA | |
| SCHEMBL2435524 | 0.77 | SMN1; SMN2 (0.37) | SMN1; SMN2TP53ALDH1A1POLBGAA | |
| SCHEMBL2434568 | 0.76 | SMN1; SMN2 (0.38) | SMN1; SMN2TP53ALDH1A1POLBGAA | |
| SCHEMBL2433811 | 0.75 | SMN1; SMN2 (0.37) | SMN1; SMN2TP53ALDH1A1POLBGAA | |
| SCHEMBL2431990 | 0.75 | SMN1; SMN2 (0.41) | SMN1; SMN2TP53ALDH1A1POLBGAA | |
| SCHEMBL2431988 | 0.75 | SMN1; SMN2 (0.41) | SMN1; SMN2TP53ALDH1A1POLBGAA | |
| SCHEMBL244740 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1346982-B1 | VLA-4 INHIBITORS | DAIICHI SEIYAKU CO (JP) | 2011-09-14 | — | — | EP | disclosed |
| US-7157487-B2 | Vla-4 inhibitors | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-01-02 | — | — | US | disclosed |
| US-20040110945-A1 | Vla-4 inhibitors | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-06-10 | — | — | US | disclosed |
| EP-1346982-A1 | VLA-4 INHIBITORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110945-A1 | Vla-4 inhibitors | VCAM1, ITGA1, ITGB4 | SMN1; SMN2 3702/4885TP53 3952/4885ALDH1A1 981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.